190 related articles for article (PubMed ID: 17896982)
21. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
Coll T; Rodrïguez-Calvo R; Barroso E; Serrano L; Eyre E; Palomer X; Vázquez-Carrera M
Curr Mol Pharmacol; 2009 Jan; 2(1):46-55. PubMed ID: 20021445
[TBL] [Abstract][Full Text] [Related]
22. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Luquet S; Lopez-Soriano J; Holst D; Gaudel C; Jehl-Pietri C; Fredenrich A; Grimaldi PA
Biochimie; 2004 Nov; 86(11):833-7. PubMed ID: 15589693
[TBL] [Abstract][Full Text] [Related]
23. Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome.
Grewal AS; Beniwal M; Pandita D; Sekhon BS; Lather V
Med Chem; 2016; 12(1):3-21. PubMed ID: 26004782
[TBL] [Abstract][Full Text] [Related]
24. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
25. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Li Z; Ren Q; Zhou Z; Cai Z; Wang B; Han J; Zhang L
Eur J Med Chem; 2021 Dec; 225():113807. PubMed ID: 34455359
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
[TBL] [Abstract][Full Text] [Related]
27. The contrasting roles of PPARδ and PPARγ in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue.
Roberts LD; Murray AJ; Menassa D; Ashmore T; Nicholls AW; Griffin JL
Genome Biol; 2011 Aug; 12(8):R75. PubMed ID: 21843327
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).
Lamers C; Schubert-Zsilavecz M; Merk D
Expert Opin Ther Pat; 2012 Jul; 22(7):803-41. PubMed ID: 22697317
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
30. Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARα, PPARγ, and PPARδ Receptors.
Grether U; Benz J; Hartung T; Roth D
Methods Mol Biol; 2023; 2576():145-153. PubMed ID: 36152183
[TBL] [Abstract][Full Text] [Related]
31. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of the ligand-binding domain of human peroxisome proliferator-activated receptor δ in complexes with phenylpropanoic acid derivatives and a pyridine carboxylic acid derivative.
Oyama T; Takiguchi K; Miyachi H
Acta Crystallogr F Struct Biol Commun; 2022 Feb; 78(Pt 2):81-87. PubMed ID: 35102897
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
Kasuga J; Nakagome I; Aoyama A; Sako K; Ishizawa M; Ogura M; Makishima M; Hirono S; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Aug; 15(15):5177-90. PubMed ID: 17532641
[TBL] [Abstract][Full Text] [Related]
34. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.
Luquet S; Gaudel C; Holst D; Lopez-Soriano J; Jehl-Pietri C; Fredenrich A; Grimaldi PA
Biochim Biophys Acta; 2005 May; 1740(2):313-7. PubMed ID: 15949697
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.
Takahashi S; Tanaka T; Kodama T; Sakai J
Pharmacol Res; 2006 Jun; 53(6):501-7. PubMed ID: 16713711
[TBL] [Abstract][Full Text] [Related]
36. Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia.
Doktorova M; Zwarts I; Zutphen TV; Dijk THV; Bloks VW; Harkema L; Bruin A; Downes M; Evans RM; Verkade HJ; Jonker JW
Sci Rep; 2017 Apr; 7(1):846. PubMed ID: 28404991
[TBL] [Abstract][Full Text] [Related]
37. PPAR delta agonists and metabolic diseases.
Kang K; Hatano B; Lee CH
Curr Atheroscler Rep; 2007 Jan; 9(1):72-7. PubMed ID: 17169250
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
40. The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor.
Liu Y; Colby JK; Zuo X; Jaoude J; Wei D; Shureiqi I
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
